On May 17, 10:41=A0am, ironjustice <teamtan...@hotmail.com>
wrote:Curious this drug mycophenolate mofetil is used to treat organ
transplant rejection JUST
LIKE iron chelators are used to treat organ transplant rejection.<<
Hmmm ..
Impairment of mycophenolate mofetil absorption by iron ion .
Clinical Pharmacology & Therapeutics , Volume 68 , Issue 6 , Pages 613
- 616
M . Morii
Who loves ya.
Tom
Jesus Was A Vegetarian!
http://tinyurl.com/2r2nkh
Man Is A Herbivore!
http://tinyurl.com/a3cc3
DEAD PEOPLE WALKING
http://tinyurl.com/zk9fk
> On May 16, 2:55=A0pm, <Cabbi> wrote:
> =A0I'm sorry if the target audience for this seems too narrow, but
> casting a
> =A0wider net lowers the chances of this happening to anyone else.
>
> =A0So, moms or potential moms being treated for SLE, please be advised
> of the
> =A0below:http://www.fda.gov/medwatch/safety/2008/
> safety08.htm#chronological
>
> =A0Cabbi <<
>
> Curious this drug is used to treat organ transplant rejection JUST
> LIKE iron chelators are used to treat organ transplant rejection.
>
> Some of these chelators cause some real problems .
>
> Mycophenolate Mofetil [MMF] (marketed as CellCept)
> Mycophenolic Acid [MPA] (marketed as Myfortic)
> Inosine Monophosphate Dehydrogenase Inhibitors (IMPDH)
> Immunosuppressants
>
> Audience: Transplantation specialists, infectious disease specialists,
> other healthcare professionals
> [Posted 05/16/2008] FDA is aware of reports of infants born with
> serious congenital anomalies, including microtia and cleft lip and
> palate, following exposure to mycophenolate mofetil (MMF) during
> pregnancy. MMF, the active drug substance in CellCept, is an ester of
> the active metabolite mycophenolic acid (MPA), the active drug
> substance in Myfortic. In most cases, the mothers were taking MMF
> following an organ transplant to prevent organ rejection. However,
> some mothers taking MMF were being treated for immune-mediated
> conditions such as systemic lupus erythematosus (SLE) and erythema
> multiforme. Treatment began before their pregnancies and continued
> into the first trimester or until the pregnancy was detected. MMF and
> MPA increase the risk of spontaneous abortion in the first trimester
> and can cause congenital malformations in the offspring of women who
> are treated during pregnancy.
>
> FDA is continuing to work with the manufacturers of these drug
> products to develop and implement means to mitigate the risks of fetal
> exposure. See the FDA Healthcare Professional Information Sheet
> containing considerations and recommendations for clinicians prior to
> prescribing MMF or MPA to women of childbearing potential.
>
> [May 16, 2008 - Healthcare Professional Sheet - FDA]
>
> -----------------------------
>
> http://www.annals.org/cgi/content/full/120/6/490
>
> Iron-Chelating Agents in Non-Iron Overload Conditions
>
> Rheumatoid Arthritis
> Anthracycline Cardiac Poisoning
> Reperfusion Injury
> Antiproliferative Effects
> Solid Tumors
> Hematologic Malignancies
> Antiprotozoal Activity
> Aluminum Chelation
> Renal Failure
> Alzheimer Disease
> Myelofibrosis and Myelodysplastic Syndrome
> Multiple Sclerosis
> Drug-induced Lung Injury
> Immunomodulatory Properties and Transplant Rejection
> Preservation of Organs for Transplant
> Glomerulonephritis
>
> Who loves ya.
> Tom
>
> Jesus Was A Vegetarian!http://tinyurl.com/2r2nkh
>
> Man Is A Herbivore!http://tinyurl.com/a3cc3
>
> DEAD PEOPLE WALKINGhttp://tinyurl.com/zk9fk